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Abstract 
Background: Despite strong evidence to designate statin use for secondary prevention 
of cardiovascular disease as “effective care” observational studies show that many 
patients with cardiovascular disease do not receive statins.  This suggests that statin 
prescribing decisions for complex cardiovascular disease patients are preference 
sensitive.  
Objectives:  To evaluate local area variation in statin prescribing for subsets of complex 
patients after acute myocardial infarction to assess whether current statin prescribing 
patterns fit profiles of either “effective care” or “preference-sensitive care” 
Research Design/Subjects: Retrospective cohort study of 124,618 Medicare patients 
with fee-for service Parts A, B, and D benefits who were hospitalized with AMI in 2008 
or 2009 with no evidence of AMI in the past 12 months.  
Measures: Patient complexity was defined by the presence of diabetes, heart failure, 
and chronic kidney disease in the year before AMI admission.  Local area practice 
styles for “no statin”, “lower-intensity statins”, and “high-intensity statins” were measured 
using the Driving Area for Clinical Care method.  Statin prescribing rates for complex 
patient subsets were contrasted across patients grouped by local areas practice styles. 
Results: Lower statin treatment rates are observed for patients with complex conditions, 
especially among those with heart failure.  However, substantial local area variation in 
statin prescribing is observed across all complex patient groups. 
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Conclusion:  Despite guidelines promoting the use of statins for secondary prevention 
for CVD patients, substantial local area variation suggests that patient and provider 
beliefs and preferences weigh heavily in statin prescribing decisions.  
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Introduction 
 Given the strength of evidence from numerous randomized controlled trials 
(RCTs), statin use for the secondary prevention of future cardiovascular events 
for patients with cardiovascular disease (CVD) has been designated as “effective 
care”.1,2 Effective care is defined by the Dartmouth Atlas as “services of proven 
effectiveness that involve no significant tradeoffs – all patients with specific medical 
needs should receive them.” 3,4  Effective care is characterized by strong evidence that 
provides little clinical discretion so that non-medical factors should have little influence 
on treatment choice.4,5  Clinical guidelines also appear to support the effective care 
categorization of statin use for patients with CVD.6,7  In fact, it is thought that most 
patients will need a high-intensity statin to achieve their cholesterol goals.8-15 
 However, it is not clear whether the designation of statins as effective care for all 
CVD patients reflects the practice beliefs of providers.  CVD patients discharged 
from hospitals that promoted guideline care had statin discharge prescribing rates 
ranging from 77 to 90%.16-18  Only 54% of a sample of Medicare beneficiaries filled a 
statin prescription within the 30 days after an acute myocardial infarction (AMI) 
discharge,19 and only 52% of patients 65 and older in a managed care plan filled a statin 
prescription within 90 days after an AMI discharge.20  In addition, substantial geographic 
variation in statin spending per Medicare beneficiary was found.21  Lack of awareness of 
the clinical evidence does not appear to be a source of this apparent statin underuse as 
96% of physicians identify a low density lipoprotein cholesterol (LDL-C) of less than 
100 mg/dl as the treatment goal for high-risk patients.22 
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 Dartmouth provides a contrasting “preference sensitive” category of medical care 
in which treatment decisions involve tradeoffs across outcomes.4,5 It may be that the 
benefits and adverse-effect risks of statins are heterogeneous across patients and that 
providers believe that the risks of adverse effects from statins may outweigh statin 
benefits for many CVD patients.  RCTs provide some evidence of heterogeneous statin 
effects across patients. Absolute CVD benefits from statin therapy vary with patient age 
and are thought to vary with the presence of diabetes (more benefit), heart failure 
(little or no benefit), and chronic kidney disease (variable benefit).23-28  While the statin 
adverse-effect risks found in RCTs are considered small relative to statin benefits,29,30 it 
has been suggested that favorable patient selection in RCTs resulted in adverse-effect 
risk estimates that are lower than what occurs in practice.31-34  Statin adverse-effects 
have been shown to vary with statin intensity, patient age, gender, weight, health 
behaviors, comorbidities, and concomitant drug use.32,35-41  Given these potential trade-
offs, in its recommended approach for patient-centered care, the American Geriatrics 
Society Expert Panel on the Care of Older Adults with Multimorbidity used statins as an 
example of a “preference sensitive decision” that may “confer long-term benefits but 
cause short-term harm”.42   
 Given that complex CVD patients are often underrepresented in RCTs43,44 we 
theorized that greater CVD patient complexity implies greater evidence uncertainty and 
the more that statin use is considered preference-sensitive by providers.  Our objective 
was to assess whether local area statin prescribing patterns for complex patients 
discharged with acute myocardial infarction (AMI) fit profiles of either “effective care” or 
“preference-sensitive care”.  Complex AMI patients were defined here using 
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combinations of conditions suggested to affect statin effectiveness: diabetes, 
heart failure (HF), and chronic kidney disease (CKD).23-28  We hypothesized that with 
evidence less certain for complex AMI patients, statin prescribing rates after AMI will be 
lower for complex patient and that geographic variation in statin use will increase with 
patient complexity.  We also theorized that, with higher adverse-effect risks, prescribing 
rates for high-intensity statins will fall with patient complexity.  This study was approved 
by the University of Iowa Institutional Review Board. 
 
Methods 
Data and Sample  
 All Medicare claims files, enrollment information, and Part D prescription drug 
events were obtained from the Chronic Condition Data Warehouse (CCW 
www.ccwdata.org) for patients hospitalized with an AMI in 2008 and 2009 using the 
CCW definition of AMI (an inpatient stay with the primary diagnosis code 410.x1 at any 
time during the year). The acute hospital admission date for each AMI served as the 
index date for the AMI.  The length of stay for each AMI was based on all Medicare 
institutional claims (acute, long term care hospital, inpatient rehabilitation facility, critical-
access hospital, and short-term nursing facility) with overlapping admission and 
discharge dates following the initial acute hospital AMI admission. The institutional stay 
discharge date was the day the patient was discharged home.  We excluded AMIs if  
the patient (1) did not survive the AMI institutional stay; (2) had an AMI within 12 months 
prior to the index date; (3) was less than 66 years old at the index date to ensure at 
least one year of Medicare eligibility prior to the index date; (4) did not have continuous 
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Medicare Parts A and B enrollment during the 12 months prior to the index date; (5) was 
not continuously enrolled in Medicare Part D during the 6 months to the index date; and 
(6) did not have continuous Medicare Parts A, B and D enrollment during period 
from the discharge date to the minimum of the patient death month or 12 months 
after discharge. To ensure a consistent statin measurement period after  discharge we 
further excluded patients who used hospice or skilled nursing care; were readmitted to 
inpatient care; or died during the 30 days after  the institutional stay discharge date.45 
Finally, because we use driving times between ZIP codes to define local areas driving 
times have inconsistent meaning for geographically non-contiguous areas (e.g. islands 
not connected by bridges), we restricted our sample to patients living in the continental 
U.S. at AMI admission.  The final cohort was 124,813 patients. 
Patient Complexity 
 We define AMI patient complexity using combinations of diabetes, chronic kidney 
disease (CKD), and heart failure (HF) diagnosed before the index AMI.  Earlier studies 
suggested these conditions are associated with statin effectiveness.23-28  We 
modified the validated Chronic Condition Data Warehouse (CCW) definitions of 
these conditions to accommodate our 1-year look back period rather than the 2-
year period specified by CCW.  The diagnosis codes used to identify each condition 
can be found in the online, supplemental digital content Appendix.  To identify CKD we 
searched for at least one Medicare inpatient, skilled nursing facility or home health claim 
or two hospital outpatient or physician claims with the relevant diagnosis codes in any 
position on the claims. To identify HF and diabetes, we searched for at least one 
inpatient, hospital outpatient or physician claim with relevant diagnosis codes in any 
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position on the claim.  Patients were then stratified into eight complex combinations 
given these diagnoses before AMI index -  (1) no prior HF, CKD or diabetes; (2) HF 
only; (3) CKD only; (4) diabetes only; (5) HF and CKD only; (6) HF and diabetes only; 
(7) CKD and diabetes only; (8) All three prior conditions. 
 
Measures of Statin Intensity Prescribing Intent  
 Our measurement goal was to assess prescribing intent by statin intensity for 
each patient at AMI discharge. High-intensity statins were defined as those that can 
lower LDL-C by 50% or more: atorvastatin 40,80mg; and rosuvastatin 20,40mg.  Lower-
intensity statins were defined as those that lower LDL-C less than 50%: atorvastatin 10, 
20mg; fluvastatin 20,40,80mg; lovastatin 10,20,40,80mg; rosuvastatin 10; pravastatin 
10,20,40,80mg; rosuvastatin 5mg; simvastatin 5, 10,20,40,80mg.10  To measure 
prescribing intent we used (1) Part D claims during 30 days after the AMI discharge 
date; and (2) estimates of statins available to the patient at home at AMI discharge 
based on previous prescription dates and days supplied on Part D claims. Two binary 
treatment variables (lower and high) were specified for each patient.  If a patient’s 
first statin prescription after discharge was a high-intensity statin or if a patient 
filled two or more lower-intensity statin prescriptions of the same drug within 2 
days of the first statin prescription with doses summing to high (e.g. two 
atorvastatin 20mg prescriptions), the patient was assigned lower = 0 and high = 1.  
All other statin prescription combinations during the 30 days after AMI discharge 
resulted in lower = 1 and high = 0.  It was also possible that a patient was prescribed a 
statin on AMI discharge but had sufficient statins at home to cover the first 30 days after 
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AMI discharge. To account for this, if a patient had no statin prescriptions in the 30 days 
after discharge and had at least 30-days of a high-intensity statin at home, the patient 
was assigned lower = 0 and high = 1.  Likewise, if a patient had no statin prescriptions 
in the 30 days after discharge and had at least 30 days of a lower-intensity statin at 
home at the patient was assigned lower = 1 and high = 0. All other patients were 
assigned as “no statin” or lower = 0 and high = 0.   
Local Area Practice Style Measures of Statin Intensity 
 We measured local area statin practice style as the average intent of physicians 
in the local area around each patient resident ZIP code to prescribe statins by intensity 
at AMI discharge. Because discharge prescribing intent is less clear for patients with 
statins available at home on discharge, we used only the patients with no statins at 
home on their AMI discharge date (N=79,285) in our measures. Practice styles were 
measured at the patient ZIP code-level using the driving area for clinical care (DACC) 
method.46  The DACC method creates “local areas” around each patient residence ZIP 
code by consecutively adding patients from the next closest ZIP codes based on driving 
times between zip codes until a threshold number of patients have been reached.46  
Local area practice style measures based on the DACC method have explained a larger 
portion of treatment variation than other local area definitions and effectively balanced 
measured covariates.46-48  We used a local area size threshold of 100 patients.  For the 
patients in the local areas around each ZIP code using the DACC method, area 
treatment ratios (ATR) for “no statin”, “lower-intensity statins” and “high-intensity statins” 
were estimated.  Each ATR was calculated as the ratio of the number of patients in the 
local area around a ZIP code that received the respective statin intensity after AMI over 
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the sum across these patients of their predicted probabilities of receiving that statin 
intensity after AMI. Probabilities were assigned to each patient of receiving no statins, a 
lower-intensity statin, and a high-intensity statin based their baseline covariates using a 
multinomial model of statin intensity choice. The multinomial model specified 
measures for patient demographics; baseline comobidities for both the year prior 
to the AMI admission and during the index AMI stay including conditions 
described as statin side effects (myopathy, rhabdomyolysis, renal events, and 
hepatic events); medications used during the 180 days prior to the AMI admission; AMI 
diagnosis-type on admission; procedures during the AMI stay; complications during the 
AMI stay; the number days of the AMI institutional length of stay spent in intensive care 
and critical care; other medications filled immediately post discharge (beta blockers, 
renin-angiotensin system antagonists); Part D variables including premium levels, 
benefit phase at AMI index date and beneficiary accumulated total and out-of-pocket 
drug costs prior to AMI index; whether patients were Medicaid dual-eligible in their AMI 
index month; patient low-income status, and socioeconomic characteristics for each 
patient residence zip code (per capita income, poverty rate, education level, English 
speaking percentage, rural/urban residence, life expectancy).  Full definitions of these 
variables are included in the online, supplemental digital content Appendix. A ZIP code 
with an ATR greater than 1 for a specific statin intensity had a local area practice style 
in which that statin intensity was used at a rate higher than average given the baseline 
characteristics of the patients in the local area. A ZIP code with an ATR less than 1 had 
a local area practice style in which the respective statin intensity was used less than 
average. 
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Analysis 
 Patients in our full sample (N=124,813) were assigned the ATR values for 
no-statin, lower-intensity statins, and high-intensity statins based on their 
residence ZIP code.  We then stratified our sample by patient complexity based 
on combinations of prior CKD, HF and diabetes.  For each complex patient 
combination we estimated treatment rates by statin intensity.  Patients were 
grouped based on the quintiles across the full sample of each statin-intensity 
specific ATR.  We then estimated treatment rates by statin intensity for each 
complex patient combination across ATR quintiles and report the range in 
variation in statin treatment rates across quintiles by statin intensity. 
Results 
 Table 1 contains the characteristics of our sample by available statin-intensity 
after AMI discharge.  Statins were not available to 38% of patients in our sample, a 
lower-intensity statin was available to 50%, and a high-intensity statin was available to 
12%.  Patients with a statin available after  discharge tended to be younger; had fewer 
comobidities (lower Charlson score); were more likely free of the 3 complex conditions 
(heart failure, CKD, diabetes); had fewer conditions before AMI or during their AMI stay 
that are considered statin adverse-effects; appeared to have more severe AMIs as 
indicated by a higher percentage of patients having an anterior wall AMI, a lower 
percentage having a non-ST elevation AMI, and higher percentage having cardiac 
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catheterization during their AMI stay; and were less likely to live in a low income ZIP 
Code. In addition, patients with a history of statin use were more likely to have statins 
available after discharge. 
 Table 2 shows the distribution of patient characteristics after grouping patients by 
the high-intensity statin area treatment ratio (ATR) associated with their residence ZIP 
code.  The percentage of patients that had a high-intensity statin available after 
AMI discharge varied from 6% to 20% across the quintiles. The ZIP code with the 
highest high-intensity ATR had a high-intensity statin treatment rate of 33% 
whereas the local areas around 73 ZIP codes had high-intensity statin treatment 
rates of zero.  Trends in the measured covariates remained across the patients 
grouped by quintiles of the high-intensity statin ATR, but these differences are 
small relative to the covariate differences when patients were grouped by 
available statin intensity in Table 1.49  Similar findings of smaller covariate 
variation were observed when patients were grouped by the “no statin” and low-
intensity statin ATRs (not shown).  “No statin” treatment rates ranged from 21% to 
69% across the ZIP codes with the minimum and maximum “no statin” ATRs, 
respectively, and low-intensity statin treatment rates ranged from 15% to 61% across 
ZIP codes with the minimum and maximum low-intensity statin ATRs, respectively. 
Figures 1 and 2 contain maps of the northeastern portion of the United States showing 
the quintile groups of the high-intensity ATR and no-statin ATRs, respectively.  These 
maps illustrate substantial with-region variation in local area statin practice styles.  
Average “no statin” treatment rates in Figure 2 were 32% in the white areas (1st quintile) 
and 44% in the dark green areas (5th quintile). 
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 Table 3 shows the percentages of patients with statins available after AMI 
discharge for the full sample, the sample stratified by whether patients had each prior 
complex condition (CKD, heart failure, and diabetes); and the sample stratified into 
complex combinations. Table 3 also shows the range in treatment rates between the 
first and fifth quintiles by statin intensity for each respective ATR-based local area 
practice measure. While 61.9% of our sample had a statin available after AMI 
discharge, rates were lower for patients with prior complex conditions. Nearly 70% of 
patients without heart failure, diabetes, or CKD before AMI had a statin available after  
discharge, whereas, only 56.6% of patients with heart failure, 57.2% of patients with 
CKD, 61.5% of patients with diabetes had a statin available after  discharge.  
Comparing rates across complex combinations shows lower statin rates occur mainly 
for patients with prior heart failure or CKD.  Specifically, patients with both prior heart 
failure and CKD had the lowest percentage of statin availability after AMI discharge 
(52.6%), followed by patients with HF only (56.5%), and patients with all 3 prior 
conditions (56.5%).  Patients with only diabetes before AMI had statin availability rates 
similar to patients with no prior conditions (68.5%).  Patients with heart failure and CKD 
also had the lowest high-intensity statin treatment rate (9.3%) and patients with no prior 
conditions and patients with only prior diabetes had the highest high-intensity statin 
treatment rates (14.1% and 14.0%, respectively).   
 Substantial geographic variation in statin availability existed across all complex 
combinations after AMI discharge, but the extent of geographic variation was not 
consistent across the complex combinations.  For both the low-intensity statin and high-
intensity statin ATRs, the largest rate difference across quintiles was for patients with no 
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prior heart failure, CKD, or diabetes (18 percentage points).  Geographic variation in 
statin use was lowest in more complex patient groups.  For example, patients with all 3 
prior complex conditions had the lowest rate difference in lower-intensity statins across 
local area quintiles (11 percentage points) and the second lowest rate difference in 
high-intensity statins across quintiles (11 percentage points).  Patients with prior HF and 
CKD only had lowest had the lowest rate difference in high-intensity statins across 
quintiles (10 percentage points). 
 
Discussion 
 Our objective was to assess whether local area statin prescribing patterns for 
complex patients discharged with acute myocardial infarction (AMI) fit profiles of either 
“effective care” or “preference-sensitive care”.4,5  Close to 62% of the Medicare patients 
in our sample had a statin available during the 30-days after discharge for AMI.  This 
percentage ranged from 69.8% for patients without heart failure, diabetes and CKD, to 
little more than half (52.6%) for patients with previous heart failure and CKD.  Given that 
most providers are aware of the cholesterol reduction goals for high-risk CVD patients, 
22 these rates suggest that both perceived benefits and risks associated with statins are 
being incorporated into prescribing decisions. Our finding of lower statin rates for more 
complex patients supports this idea as statin adverse-effect risks have been shown to 
increase with patient complexity.32,35-41  It is noted that prior diabetes had little effect 
on statin rates is consistent with studies suggesting that statin benefits are 
enhanced for diabetic patients.23-25 In addition, substantial geographic variation in 
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statin availability after AMI was found across the entire sample and within each complex 
combination.  These results suggest that differences exist across local areas in either 
the beliefs on relationships between statins and outcomes or in the preferences that 
providers and patients have over the outcomes associated with statin use.  Interestingly, 
the extent of geographic variation in statin use was lower for more complex patients.  
There appears to be more agreement across local areas in the lower statin treatment 
rates for more complex patients than the higher statin treatment rates for the less 
complex patients.   
 The ability to make inferences on variation in provider beliefs in this study is 
limited by the inability of our measures to differentiate between physician and patient 
choices.  The measures used here reflect both physician prescribing behavior and the 
willingness of patients to fill statin the prescriptions they received.  Our statin use 
measures understate the prescribing intent of physicians to the extent that prescriptions 
are unfilled by the patient. In addition, it also is possible that the geographic 
variation in statin use we found could be partially attributable to geographic 
variation in unmeasured conditions like patient frailty.  
 Statin rates that diminish with patient complexity and the substantial local area 
variation in statin rates suggest that providers consider statins to be more “preference–
sensitive care” than “effective care” for secondary prevention of cardiovascular disease.    
Local area variation in statin use exists across all groups of complex AMI patients. 
However, our results do not say whether current statin utilization rates represent a 
correct balancing of statin benefits and risks across complex AMI patients. Further 
research is needed to assess whether many complex AMI patients in areas with low 
This is a final peer-reviewed manuscript.  
For a published version, please go to http://journals.lww.com/lww-
medicalcare/Abstract/2014/03001/Geographic_Variation_in_Statin_Use_for_Complex.9.aspx. 
17 
 
statin utilization rates are missing benefit opportunities or, in contrast, whether many 
complex AMI patients in areas with high statin utilization rates and suffering adverse 
side effects with little benefit gain.  In context of statin use for secondary prevention of 
cardiovascular disease for complex patients, this question is analogous to the question 
stated many years ago by John Wennberg, “Which rate is right?”.50   
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Table 1: Characteristics of Medicare AMI Patients 2008-2009 by Intensity of Initially-Prescribed Statina 
  
Intensity of Initially-Prescribed Statin 
Availability After AMI Discharge 
 
 
Total 
Population  
None Lower High P-valueh 
N 124,813 47,566 62,316 14,931  
Treatment     <0.0001* 
   No Statin % 38 100 0 0  
   Lower-Intensity Statina % 50 0 100 0  
   High-Intensity Statina % 12 0 0 100  
Age     <0.0001* 
    66-75 % 41 33 44 52  
    76-85 % 39 39 39 37  
    86+ % 21 28 17 12  
Gender     <0.0001* 
     Male % 43 40 45 49  
     Female % 57 60 55 51  
Charlson Scoreb     <0.0001* 
    0 % 33 28 36 38  
    1+ % 67 72 64 62  
Complex Patient Combinationsc     <0.0001* 
  No Prior Heart Failure, CKD or Diabetes 
% 
25 20 28 30  
  Heart Failure only % 16 19 15 14  
  CKD only % 5 5 5 5  
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  Diabetes only % 12 10 13 14  
  Heart Failure and CKD only % 10 12 9 8  
  Heart Failure and Diabetes only % 12 13 12 11  
  CKD and Diabetes only % 5 5 5 5  
  Heart Failure, CKD and Diabetes % 15 17 14 13  
Arterial Wall AMId % 6 4 7 9 <0.0001* 
NSTEMI AMIe % 76 80 74 70 <0.0001* 
Catheterization During Index Stay % 59 44 67 75 <0.0001* 
Statin Rx in 180 Days Prior to Index 
AMI % 
47 26 60 59 
<0.0001* 
Conditions Related to Statin Side-
Effects 
    
 
   Pre-Index AMIf % 23 26 21 19 <0.0001* 
   During Index AMfI % 20 23 18 17 <0.0001* 
Low Income Zip Codeg % 50 51 49 46 <0.0001* 
a.  Based on highest statin intensity in 30 days post-index stay discharge or intensity of available 30-day supply available prior to discharge. 
b.  Klabunde CN et al. Development of a comorbidity index using physician claims data. Journal of Clinical Epidemiology, 200 Dec; 53(12) 
1258-67. 
c.  HF: Heart Failure: CKD: Chronic Kidney Disease. See Appendix for CKD, HF, and diabetes ICD-9 codes 
d.  ICD-9 codes 410.0 410.1 
e.  ICD-9 410.7x 
f    acute renal failure/acute tubular necrosis ICD-9 584.xx; acute glomerulonephritis ICD-9 580.xx. Myopathy: ICD-9-CM 728.89, 729.1, 
359.4,359.8, 359.9, 710.4, 728.9, 729.8X, E942.2; CPT codes 82550, 82552, 82554, 80012, 80016, 80018, or 80019. Acute/sub-acute 
necrosis of liver ICD-9 570.xx; hepatitis ICD-9 573.3x; other disorders of liver ICD-9 573.8x, 573.9x. 
g.  Percentage of low income residents was above median in 2000 for beneficiary zip code. 
h.  Pearson Chi-Square statistic calculated by estimating the expected number of observations in each cell of an R-by-C table, and 
comparing these values with the observed number of observations in each cell of the table. The p-value is estimated using the Chi-
Square distribution with (R-1)*(C-1) degrees of freedom. 
 *   p < .05 
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Table 2: Characteristics of Medicare AMI Patients 2008-2009 by Local Area High-Intensity Prescribing Style 
  
Quintile of High-Intensity Statin Area 
Treatment Ratio 
(Higher Area Treatment Ratio (ATR)→)  
 
 Total Population  1st 2nd 3rd 4th 5th P-valueh 
N 124,813 24,693 24,691 24,693 24,692 24,694  
High-Intensity Statin Average 
Area Treatment Ratio 
1 0.36 0.67 0.93 1.24 1.84 <0.0001* 
Treatment        
   No Statin % 38 40 39 39 38 36 <0.0001* 
   Lower-Intensity Statina % 50 54 52 50 48 45 <0.0001* 
   High-Intensity Statina % 12 6 9 11 14 20 <0.0001* 
Age        
    66-75 % 41 41 42 41 41 39 <0.0001* 
    76-85 % 39 39 38 39 38 40 0.0609 
    86+ % 21 20 20 20 21 22 <0.0001* 
Sex        
     Male % 43 44 44 43 43 42 <0.0001* 
     Female % 57 56 56 57 57 58 <0.0001* 
Charlson Scoreb        
    0 % 33 36 34 33 33 31 <0.0001* 
    1+ % 67 64 66 67 67 69  
Complex Patient Combinationsc       <0.0001* 
  No Prior Heart Failure, CKD or 
Diabetes % 
25 27 25 25 24 23  
  Heart Failure only % 16 17 16 16 16 16 0.0775 
  CKD only % 5 5 5 5 5 5 0.3946 
  Diabetes only % 12 12 12 11 12 11 0.5881 
  Heart Failure and CKD only % 10 9 10 10 10 11 0.0015* 
  Heart Failure and Diabetes only % 12 11 12 12 12 13 <0.0001* 
  CKD and Diabetes only % 5 5 5 5 5 5 0.3813 
This is a final peer-reviewed manuscript.  
For a published version, please go to http://journals.lww.com/lww-medicalcare/Abstract/2014/03001/Geographic_Variation_in_Statin_Use_for_Complex.9.aspx. 
21 
 
  Heart Failure, CKD and Diabetes 
% 
15 14 15 15 16 16 <0.0001* 
Arterial Wall AMId % 6 6 6 6 6 6 <0.0269* 
NSTEMI AMIe % 76 74 75 76 76 78 <0.0001* 
Catheterization During Index Stay 
% 
59 62 60 60 58 56 <0.0001* 
Statin Rx in 180 Days Prior to 
Index AMI % 
47 45 47 47 47 50 <0.0001* 
Conditions Related to Statin 
Side-Effects 
       
   Pre-Index AMIf % 23 22 23 23 23 24 <0.0001* 
   During Index AMfI % 20 18 20 20 20 21 <0.0001* 
Low Income Zip Codeg % 50 52 50 51 50 46 <0.0001* 
a.  Based on highest statin intensity in 30 days post-index stay discharge or intensity of available 30-day supply available prior to discharge. 
b.  Klabunde CN et al. Development of a comorbidity index using physician claims data. Journal of Clinical Epidemiology, 200 Dec; 53(12) 
1258-67. 
c.  HF: Heart Failure: CKD: Chronic Kidney Disease. See Appendix for CKD, HF, and diabetes ICD-9 codes 
d.  ICD-9 codes 410.0 410.1 
e.  ICD-9 410.7x 
f    acute renal failure/acute tubular necrosis ICD-9 584.xx; acute glomerulonephritis ICD-9 580.xx. Myopathy: ICD-9-CM 728.89, 729.1, 
359.4,359.8, 359.9, 710.4, 728.9, 729.8X, E942.2; CPT codes 82550, 82552, 82554, 80012, 80016, 80018, or 80019. Acute/sub-acute 
necrosis of liver ICD-9 570.xx; hepatitis ICD-9 573.3x; other disorders of liver ICD-9 573.8x, 573.9x. 
g.  Percentage of low income residents was above median in 2000 for beneficiary zip code. 
h.  Cochran-Armitage test of trend in characteristic value across patients grouped into quintiles based on local area high-intensity practice style 
measure.  For example, the p value for Age 76-85 tests whether a linear trend in the percentage of patients in this age group exists across 
quintiles of the high-intensity ATR-based patient groups 
*   p < .05 
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Table 3: Geographic Variation in Statin Intensity Treatment Rates for Medicare AMI 
Patients post-Discharge by Patient Complexity 
 N 
% No Statin 
(1
st
–5
th
 quintile range)
a 
% Lower-Intensity 
Statin 
(1
st
 – 5
th
 quintile range)
b 
% High-Intensity 
Statin  
(1
st
 – 5
th
 quintile range)
c 
Full Sample 124,813 
38.1 (32 - 44) 49.9 (43 - 57) 12.0 (6 - 20) 
Patients with 
Prior Condition 
    
Prior HF 66,644 43.4 (36-49) 46.1 (40-53) 10.5 (6-17) 
Prior Diabetes 54,125 38.6 (33-44) 49.5 (43-55) 12.0 (7-19) 
Prior CKD 43,690 42.8 (36-49) 46.5 (41-53) 10.7 (6-17) 
Complex 
Combinations 
    
No HF, CKD or D 31,170 30.2 (24 - 37) 55.7 (47 - 65) 14.1 (6 - 24) 
HF only 20,451 
43.4 (35 - 51) 46.2 (39 - 55) 10.3 (5 - 18) 
CKD only 6,597 
37.8 (33 - 44) 50.4 (43 - 57) 11.9 (6 - 21) 
D only 14,364 
31.4 (26 - 38) 54.5 (46 - 62) 14.0 (8 - 23) 
HF and CKD only 12,470 47.4 (39 - 54) 43.3 (38 - 51) 9.3 (5 - 15) 
HF and D only 15,138 
40.1 (34 - 45) 48.7 (43 - 55) 11.3 (7 - 18) 
CKD and D only 6,038 
36.4 (32 - 43) 51.2 (45 - 58) 12.4 (8 - 20) 
HF, CKD, and D 18,585 43.5 (38 - 49) 45.7 (40 - 51) 10.8 (6 - 17) 
a. No statin area treatment rate (ATR) quintiles. 
b. Low-intensity statin area treatment rate (ATR) quintiles. 
c. High-intensity statin area treatment rate (ATR) quintiles. 
HF: heart failure; CKD: chronic kidney disease; D: diabetes 
This is a final peer-reviewed manuscript.  
For a published version, please go to http://journals.lww.com/lww-
medicalcare/Abstract/2014/03001/Geographic_Variation_in_Statin_Use_for_Complex.9.aspx. 
23 
 
Figure 1:   Northeastern United States High-Intensity Statin Area Treatment Ratios 
by  ZIP Code. 
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Figure 2:  Northeastern United States “No Statin” Area Treatment Ratios by ZIP 
Code.  
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